Method for the mitigation of symptoms of contact lens related dry eye

• US 20070043140A1
• Filed: 02/06/2006
• Published: 02/22/2007
• Est. Priority Date: 03/02/1998
• Status: Abandoned Application

• Current Assignee: Johnson & Johnson Vision Care Incorporated (Johnson & Johnson)
• Original Assignee: Johnson & Johnson Vision Care Incorporated (Johnson & Johnson)
• Inventors: Copper, Lenora, Steffen, Robert, Lorenz, Kathrine, McCabe, Kevin
• Application Number:
  US11/347,973
• Publication Number:
  US 20070043140A1
• Time in Patent Office: Days
• US Class Current: 523/106
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: G02B 1/043 Contact lenses

Abstract

The present invention relates to method for the treatment of contact lens related dry eye comprising contacting the surface of the eye of a patient in need of treatment for contact lens related dry eye with a contact lens having specified properties.

Claims

1. A method for the mitigation of symptoms of contact lens related dry eye comprising contacting the surface of the eye of a patient in need of mitigation of symptoms for contact lens related dry eye with a contact lens comprising senofilcon A.

2. The method of claim 1 wherein said symptoms include dryness, burning, stinging and discomfort.

3. The method of claim 1 wherein said contacting step comprises a wear time of at least about 8 hours.

4. The method of claim 1 wherein said contacting step comprises a wear time of at least about 12 hours.

5. The method of claim 1 wherein said contacting step comprises a wear time of at least about 24 hours.

6. The method of claim 1 wherein said contacting step comprises a wear time of at least about 1 week.

7. The method of claim 1 wherein said contacting step comprises a wear time of at least about 1 month.

8. The method of claim 1 wherein said patient is in need of mitigation of symptoms of excessive tear evaporation.

9. The method of claim 1 wherein said patient is in need of mitigation of symptoms of Non-Sjogren'"'"'s aqueous tear deficiency.

10. A method for the mitigation of symptoms of contact lens related dry eye comprising contacting the surface of the eye of a patient in need of mitigation of symptoms for contact lens related dry eye with a contact lens comprising a modulus of less than about 120 psi and at least about 5% of at least one lubricious polymer.

11. The method of claim 10 wherein said contact lens comprises at least one silicone containing component.

12. The method of claim 10 wherein said mitigation of symptoms comprises improvement in end of day wearing comfort as measured by a preference for the contact lens of claim 10 of at least about 1.5 to 1 compared to an etafilcon A contact lens, when measured in a double masked, clinical trial with at least about 20 patients wearing the lenses for one week in daily disposable mode.

13. The method of claim 10 wherein said mitigation of symptoms comprises improvement in overall comfort as measured by a preference for the contact lens of claim 10 of at least about 1.5 to 1 compared to an etafilcon A contact lens, when measured in a double masked, clinical trial with at least about 20 patients wearing the lenses for one week in daily disposable mode.

14. The method of claim 10 wherein said mitigation of symptoms comprises improvement in initial comfort as measured by a preference for the contact lens of claim 10 of at least about 1.5 to 1 compared to an etafilcon A contact lens, when measured in a double masked, clinical trial with at least about 20 patients within thirty minutes of lens insertion.

15. The method of claim 10 wherein said lubricious polymer has a weight average molecular weight of at least about 50,000 Daltons.

16. The method of claim 10 wherein said lubricious polymer has a weight average molecular weight of at least about 100,000 Daltons.

17. The method of claim 10 wherein said lubricious polymer comprises a water content of at least about 70% when polymerized and crosslinked to minor amount.

18. The method of claim 10 wherein said lubricious polymer is selected from the group consisting of polyamides, polylactones, polyimides, polylactams and functionalized polyamides, polylactones, polyimides, polylactams, and copolymers thereof.

19. The method of claim 10 wherein said lubricious polymer is selected from the group consisting of poly-N-vinyl pyrrolidone, poly(N-vinyl-N-methylacetamide), poly-N-vinyl-2-piperidone, poly-N-vinyl-2-caprolactam, poly-N-vinyl-3-methyl-2-caprolactam, poly-N-vinyl-3-methyl-2-piperidone, poly-N-vinyl-4-methyl-2-piperidone, poly-N-vinyl-4-methyl-2-caprolactam, poly-N-vinyl-3-ethyl-2-pyrrolidone, and poly-N-vinyl-4,5-dimethyl-2-pyrrolidone, polyvinylimidazole, poly-N-N-dimethylacrylamide, polyvinyl alcohol, polyethylene oxide, poly 2 ethyl oxazoline, heparin polysaccharides, polysaccharides, mixtures and copolymers (including block or random, branched, multichain, comb-shaped or star shaped) thereof.

20. The method of claim 10 wherein said lubricious polymer comprises repeating units derived from N-vinylpyrrolidone, N-vinyl-N-methylacetamide and mixtures thereof.

21. The method of claim 10 wherein said mitigation of symptoms comprises improvement in dryness as measured by a preference for the contact lens of claim 10 of at least about 1.5 to 1 compared to an etafilcon A contact lens, when measured in a double masked, clinical trial with at least about 20 patients for one week in daily disposable mode.